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Abstract
Background and Objective Non-participation in colorectal cancer (CRC) screening needs to be decreased to achieve its full 
potential as a public health strategy. To facilitate successful implementation of CRC screening towards unscreened individu-
als, this study aimed to quantify the impact of screening and individual characteristics on non-participation in CRC screening.
Methods An online discrete choice experiment partly based on qualitative research was used among 406 representatives 
of the Dutch general population aged 55–75 years. In the discrete choice experiment, respondents were offered a series of 
choices between CRC screening scenarios that differed on five characteristics: effectiveness of the faecal immunochemical 
screening test, risk of a false-negative outcome, test frequency, waiting time for faecal immunochemical screening test results 
and waiting time for a colonoscopy follow-up test. The discrete choice experiment data were analysed in a systematic man-
ner using random-utility-maximisation choice processes with scale and/or preference heterogeneity (based on 15 individual 
characteristics) and/or random intercepts.
Results Screening characteristics proved to influence non-participation in CRC screening (21.7–28.0% non-participation 
rate), but an individual’s characteristics had an even higher impact on CRC screening non-participation (8.4–75.5% non-
participation rate); particularly the individual’s attitude towards CRC screening followed by whether the individual had 
participated in a cancer screening programme before, the decision style of the individual and the educational level of the 
individual. Our findings provided a high degree of confidence in the internal–external validity.
Conclusions This study showed that although screening characteristics proved to influence non-participation in CRC screening, 
a respondent’s characteristics had a much higher impact on CRC screening non-participation. Policy makers and physicians can 
use our study insights to improve and tailor their communication plans regarding (CRC) screening for unscreened individuals.
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Key Points for Decision Makers 
Although screening characteristics proved to influence 
non-participation in colorectal cancer screening, an 
individual’s characteristics had a much higher impact on 
colorectal cancer screening non-participation.
Particularly, the individual’s general attitude towards 
colorectal cancer screening and whether the individual 
had participated in a cancer screening programme before 
had a high impact on colorectal cancer screening non-
participation.
Policy makers and physicians can use these insights to 
improve and tailor their communication plans regarding 
colorectal cancer screening for unscreened individuals.
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1 Introduction
Colorectal cancer (CRC) is one of the most common causes 
of cancer death in developed countries, with approximately 
700,000 deaths worldwide in 2018 [1]. Population-based 
CRC screening is widely recommended as it can reduce the 
incidence and mortality of CRC [2–5]. There are several 
methods available for CRC screening, such as faecal testing 
(guaiac faecal occult blood testing, faecal immunochemi-
cal testing [FIT]) and endoscopic and radiologic screening 
tests (sigmoidoscopy, colonoscopy, computed tomography 
colonography) [6–11].
Participation is an important determinant of the effec-
tiveness of CRC screening programmes. If screening is 
to achieve its full potential as a public health strategy, 
non-participation in screening needs to be decreased [12]. 
To facilitate participation in CRC screening programmes 
and tailored information directed towards unscreened 
individuals, a first important step is obtaining insights 
into determinants that drive non-participation and the 
trade-offs individuals are willing to make between par-
ticipation and non-participation in population-based CRC 
screening. Non-participation is defined here as the condi-
tion of not being participating in population-based CRC 
screening. Knowing which determinants have a relatively 
high impact on non-participation will help policy makers 
and physicians to improve and tailor their communication 
plans efficiently regarding CRC screening.
The discrete choice experiment (DCE), a quantitative 
technique that is commonly used in healthcare research, is 
a useful method to obtain insights into determinants that 
have an impact on non-participation for medical interven-
tions [13]. Although several DCE studies exist concern-
ing preferences for population-based faecal screening [11, 
14–20], none of them accounted for scale effects (i.e. how 
consistent individuals make their choices) and preference 
heterogeneity (i.e. to determine whether CRC screening 
non-participation depends on specific individual charac-
teristics) simultaneously. This study provides a thorough 
analysis of the importance of such statistical model com-
ponents. Our results reveal that accounting for both scale 
effects and preference heterogeneity is needed to obtain 
internal and external valid outcomes that are useful for 
health policy decisions and communication, which vali-
dates similar findings of de Bekker-Grob et al. [21] in 
the field of influenza vaccination. This study determined 
the influence of screening and individual characteristics 
on non-participation in CRC screening via a DCE while 
incorporating these important model components into the 
statistical analysis.
2  Methods
2.1  Study Sample and Elicitation Mode
An online sample of 400 individuals aged 55–75 years (i.e. 
target population for CRC screening) from the Dutch general 
population, nationally representative in terms of age, sex, 
education and geographic region was recruited via Survey 
Sampling International, a commercial survey sample pro-
vider. This number of individuals was calculated to be suf-
ficiently large for reliable statistical analyses for our study 
[22]. Approval for the study was obtained from the Medi-
cal Ethics Committee, Erasmus MC (MEC-2016-095). All 
respondents gave their consent to participate in this study. 
The study was performed in accordance with the Declara-
tion of Helsinki.
2.2  Discrete Choice Experiment
A DCE assumes that a given medical intervention, such 
as an CRC screening programme, can be described by its 
characteristics (e.g. screening effectiveness, screening inter-
val, waiting time), and that the individual’s preference for 
a medical intervention is determined by the levels of those 
characteristics (e.g. levels for screening interval: ‘every 
year’, ‘every 2 years’ or ‘every 3 years’) [23]. The relative 
importance of these characteristics can be assessed when 
individuals are forced to make trade-offs by offering a series 
of choices between medical intervention alternatives that 
have different combinations of levels [24] (see Fig. 1 for an 
example of such a ‘choice task’).
To develop and operationalise CRC screening characteris-
tics with their levels for our DCE, we used a literature search 
(a snowball method was used) followed by interviews with 
experts in the field of CRC screening (n = 4 experts in the 
field of CRC screening to account for recent developments 
regarding FIT characteristics), and three focus groups with 
patients aged 55–75 years (n = 21) recruited from and con-
ducted in two general practices. After this qualitative work, 
the nominal group technique [25] was applied and used to 
select the most relevant CRC screening characteristics that 
may impact individuals’ decisions to (non-)participate in 
CRC screening. That is, during the group interviews, partici-
pants (i.e. the same patients aged 55–75 years [n = 21] from 
the focus groups recruited from two general practices) were 
asked to rank a number of potential attributes from most to 
least important. The mean group ranking of the attributes 
was then discussed in the group, after which participants 
could change their original individual ranking. The most rel-
evant, and hence, selected characteristics were: effectiveness 
of the FIT, risk of a false-negative FIT outcome, frequency 
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of the FIT, waiting time for FIT results and waiting time for 
a colonoscopy follow-up test. The levels for each of these 
screening characteristics incorporated the range of possi-
ble CRC screening outcomes (Table 1). These levels were 
based on the literature (see [26–28] for levels concerning 
test frequency, test efficiency and the risk of a false nega-
tive), current Dutch practice (i.e. waiting times to receive a 
FIT result and to undergo a colonoscopy) and expert opin-
ion (n = 4 experts in the field of CRC screening to account 
for recent developments regarding FIT test characteristics). 
Noteworthy, in The Netherlands, FIT is used as biannual 
population-based CRC screening test, screening participants 
aged 55–75 years do not have to pay for CRC screening and 
the participation rate for population-based CRC screening 
is 72.7% (70.3% and 75.1% participation rate for first and 
non-first invitees, respectively).
2.3  Study Design and Questionnaire
The combination of, in our case, five screening characteris-
tics with three levels each (to test for non-linearity), resulted 
in almost 30,000 unique different pair-wise comparisons (i.e. 
choice tasks; combinations of two different CRC screen-
ing alternatives). As it is not feasible to present a single 
individual with all combinations of these alternatives, a het-
erogeneous Bayesian efficient design was used that reduced 
the burden for respondents yet accommodated the reliable 
estimation of the preference parameters [29]. The prior pref-
erence information (attribute weights) as required for the 
Bayesian efficient optimisation approach was obtained from 
best guess priors using expert judgement and updated for 
this DCE study after a pilot run of 100 respondents. The 
overall DCE design comprised ten different sub-designs 
[30]. Each respondent was offered only one sub-design that 
contained 16 discrete choice tasks (Fig. 1). The ‘opt out’ 
alternative was included as CRC screening is a preventive 
intervention and, as in real life, respondents are not obliged 
to get screened for CRC. In each choice task, respondents 
were asked to choose the alternative that appealed most to 
them.
Apart from the 16 choice tasks, the questionnaire con-
tained questions on 15 respondent characteristics: nine back-
ground variables (age, sex, educational level, household, 
having had cancer, CRC in family, general practice visit last 
month, hospital visit last month and health condition); three 
CRC screening-related variables (general attitude towards 
CRC screening [31], cancer screening experience and having 
had a positive cancer screening test result before); and three 
Fig. 1  Example of a colorectal 
cancer screening choice task
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decision-making skills variables (decision style [32], health 
literacy [33, 34] and numeracy [35, 36]). The latter is impor-
tant as decisions made by respondents are widely recognised 
as being affected by individual differences, and previous 
research showed that accounting for decision style, health 
literacy, and numeracy is important to guarantee internal and 
external valid DCE outcomes [21, 37]. These 15 individual 
characteristics were of interest based on the literature [21, 
37], expert opinions and focus groups (see Sect. 2.2) and 
hypothesised to have an impact on CRC screening (non-)
participation. The questionnaire also contained a question 
that assessed the perceived difficulty of the questionnaire 
(5-point scale). The questionnaire was pilot tested (n = 20; 
the patients used for this pre-pilot study were another 20 to 
the focus groups [i.e. no overlap]) to check for any problems 
in interpretation and face validity. It was a qualitative pre-
pilot by using a think-aloud strategy to test whether patients 
understood the questionnaire and interpreted the attributes 
and levels in a manner we wanted them to. As none of the 
respondents raised any problems, no alterations were made.
2.4  Statistical Analyses
Several models exist to analyse discrete choice data [13, 38, 
39]. Each choice model has its set of features, which should 
fit the intentions of the research and match the respondents’ 
choice behavior. Given our interest in accounting for sys-
tematic preference heterogeneity (i.e. to determine whether 
CRC screening non-participation depends on specific indi-
vidual characteristics), while also taking scale effects (i.e. 
how consistent respondents make their choices), our sample 
size and the model fit into account, led to the decision to 
employ a heteroscedastic model in error component using 
Pythonbiogeme software [40]. We used a four-step approach 
to determine the optimal utility function (see Table 2). The 
final model was based on backward selection, Bayesian 
Information Criterion, and accuracy in prediction of CRC 
screening choices on an aggregate and individual level.
First, we tested several different specifications for the util-
ity function (i.e. categorical/numerical screening character-
istic levels, two-way interactions between screening char-
acteristics, several screening characteristic transformations) 
[Model A; multinomial logit model]. Second, we tested sev-
eral scale components to the utility function (Model B; het-
eroscedastic multinomial logit model). Third, we allowed for 
several covariates (15 individual characteristics) to enter the 
utility function (Model C; heteroscedastic multinomial logit 
model plus systematic preference heterogeneity). Finally, a 
random intercept was added to the utility function (Model D; 
same model as Model C but using a random intercept). The 
random intercept (alternative specific constant; ASC) took 
account of whether respondents systematically viewed the 
CRC screening alternative(s) differently from the no CRC 
screening alternative. Noteworthy, using the coefficients of 
Model D, the software Pythonbiogeme [40], the conditional 
parameter approach of Train [41] and Revelt & Train [42], 
and Excel [43], we were able to determine the ASCs per 
individual (ASC_i; hence ?̂?
n
).
For the parameter estimates (coefficients), the statisti-
cal significance (p ≤ 0.05) indicates whether respondents 
considered the characteristic(level) important in their deci-
sion to participate or not in CRC screening. The sign of the 
coefficient reflects whether the characteristic has a positive 
or negative effect on utility for CRC screening. In terms 
Table 1  Colorectal cancer 
(CRC) screening characteristics 
and its levels
Characteristics Levels
Effectiveness 20% (i.e. 67 instead of 59 of every 100 people with CRC survives)
40% (i.e. 75 instead of 59 of every 100 people with CRC survives)
60% (i.e. 83 instead of 59 of every 100 people with CRC survives)
Risk false negative (i.e. probability 
the screening test does not find the 
cancer)
15%
25%
35%
Waiting time for test results 1 week
2 weeks
3 weeks
Waiting time for follow-up test 2 weeks
4 weeks
8 weeks
Frequency of the screening Every year
Every 2 years
Every 3 years
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of the scale parameters, statistically significant parameter 
estimates indicate that the associated covariate changes the 
scale of the utility component relative to the unobserved ran-
dom component of utility. When a covariate has a positive 
(negative) coefficient, this increases (decreases) the scale of 
utility, which results in more (less) consistent choices. The 
benefit of such scale effects is that it allows some patients to 
have very clear and well-established preferences, while for 
others the comparisons and choice might be more difficult 
and hence noisier [44, 45].
2.5  Expected Non‑Participation in Colorectal Cancer 
Screening
Choice probabilities (i.e. the expected CRC screening non-
participation) were calculated to provide a method to convey 
DCE results in a more meaningful manner for policy mak-
ers and physicians. We calculated the choice probability for 
a base-case CRC screening and a base-case individual by 
taking the exponent of the total utility for CRC screening 
divided by the exponent of utility of both CRC screening 
and no CRC screening. The base-case CRC screening pro-
gramme was chosen to resemble a common Dutch practice 
situation, and included the following attribute levels: a CRC 
screening programme that has an effectiveness of 40% (i.e. 
75 instead of 59 of every 100 persons with CRC survives), a 
25% risk of a false-negative outcome, a screening frequency 
of every 2 years, a 2-week waiting time for FIT results, and a 
4-week waiting time for a colonoscopy follow-up test.
As there was no clear rationale to choose a specific base-
case individual, we decided to opt for a base-case individual 
that had all dummy-coded ‘1’ characteristics: ‘a low edu-
cated male individual aged 55–64 years with a positive atti-
tude for CRC screening, who has not had cancer. He has 
good health literacy and numeracy skills and a non-delib-
erative decision style, has screening experience, but did not 
experience a bad screening test result yet. He does not have 
CRC diagnosed in his family, has a good health condition, 
did not visit the general practitioner or hospital in the last 
month, and is living together with a partner or family mem-
ber’. To investigate the impact of changing a screening or 
an individual characteristic on CRC screening non-partici-
pation, univariate estimates (i.e. one-way impact) for pre-
dicted probability of CRC screening non-participation were 
calculated. Here, we used the same approach as described 
in de Bekker-Grob et al. [21].
3  Results
3.1  Respondents
From the total of 485 panel members aged 55–75 years who 
started the survey, 406 (83.7%) completed the question-
naire, resulting in 79 dropouts (16.3%). Less than 10% of 
respondents that completed the survey perceived filling out 
the questionnaire as difficult. Respondents had a mean age 
of 63.3 years (standard deviation = 5.4), 201 respondents 
(49.5%) were male and one-third had a lower educational 
level (Table 3).
About 74% of the respondents reported that they were 
in good health, 54 respondents (13.3%) had cancer and 298 
respondents (73.4%) mentioned that they have experience 
with cancer screening (Table 3). Ninety-three percent of the 
respondents (N = 298) stated that they would participate in 
CRC screening if received an invitation.
3.2  Discrete Choice Experiment Results
The DCE results can be found in Table 4. The main message 
of Table 4 is that (i) all screening characteristics proved to be 
important in the decision to opt in or out for CRC screening; 
(ii) the DCE results showed a high level of validity; and (iii) 
preference heterogeneity among respondents from system-
atic sources was found to be substantial. The heteroscedastic 
multinomial logit model, which included respondent char-
acteristics as well as a random intercept, resulted in the best 
model fit and prediction accuracy (see Model D, Table 4).
Focusing in more detail on Model D, all screening char-
acteristics proved to be important in the decision to opt in or 
out for CRC screening (p < 0.01). The screening characteris-
tics had the expected sign and order, and showed, therefore, 
theoretical validity. In other words, there was a higher prob-
ability to participate in CRC screening, if the CRC screen-
ing was more effective, had a smaller risk of false-negative 
outcomes and had a shorter waiting time for the colonoscopy 
follow-up test.
As a validity check, the predicted CRC screening par-
ticipation of 90.6% (confidence interval 87.4–93.3%) at an 
aggregate level was in line with the observed CRC screen-
ing participation intention of 92.9% (i.e. what respondents 
stated they will do; see previous paragraph) (Table 4). That 
is, the observed CRC screening participation on the group 
level was correctly predicted by our DCE. Additionally, this 
Table 2  Four-step approach to systematic analyse the discrete choice 
experiment datas
CRC colorectal cancer
Step Model
A B C D
1. Random utility maximization decision rule × × × ×
2. Systematic scale heterogeneity × × ×
3.  Systematic preference heterogeneity × ×
4. Random opt-out (i.e. no CRC screening) utility ×
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model also almost perfectly predicted the observed CRC 
screening participation on the respondent level (97.1% out 
of 100%). Hence, the DCE results showed a high level of 
validity.
Preference heterogeneity among respondents from sys-
tematic sources was found to be substantial (Table 4). All 
15 respondent characteristics had an impact on one or more 
screening characteristic levels, and hence directly on non-
participation in CRC screening (see next paragraph).
3.3  Impact Characteristics on Non‑Participation 
in Colorectal Cancer Screening
Screening characteristics and respondents’ characteris-
tics both influenced non-participation in CRC screening. 
Table 3  Respondents’ 
characteristics
CRC colorectal cancer, GP general practitioner, obj objective, SD standard deviation, SNS Subjective 
Numeracy Scale
N = 406 %
Male 201 49.5
Age (mean; SD) 63.3 5.4
 Aged < 65 years 234 57.6
 Aged 65 years or older 172 42.4
Education
 Low 125 30.8
 Medium 162 39.9
 High 118 29.1
Health
 Good 302 74.4
 Moderate 91 22.4
 Bad 13 3.2
Household
 Living alone 135 33.3
 Living together (with partner and/or children) 271 66.7
Visited GP last month (yes) 141 34.7
Visited hospital last month (yes) 97 23.9
Suffered from cancer (yes) 54 13.3
CRC history family member (yes) 93 22.9
Have experience with screening (yes) 298 73.4
CRC screening test asked for further research (yes) 10 2.5
Family or friends impact CRC screening decision (yes) 21 5.2
Say that s/he will opt for CRC screening (fixed choice; yes) 377 92.9
General attitude CRC screening
 In favour 357 87.9
 Neutral 44 10.8
 Against 5 1.2
Health literacy
 Average (mean; SD) 2.9 0.5
 Good health literacy (scored 3 or higher) 177 43.6
Numeracy
 SNS average (mean; SD) 4.1 1.0
 Objective scores correct (yes) 271 66.7
 Good numeracy (i.e. 4 or higher SNS + obj scores correct [yes]) 257 63.3
Decision style
 Decision style average (mean; SD) 3.0 0.5
 Rather deliberative (> 3) 138 34.0
 Neutral (3) 120 29.6
 Rather intuitive (< 3) 148 36.5
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Table 4  Discrete choice experiment result
Utility function Model A Model B Model C Model D
Model MNL model HMNL model HMNL model + 
systematic preference 
heterogeneity
HMNL model + 
systematic preference 
heterogeneity + random 
opt-out utility
Coeff value p value Coeff value p value Coeff value p value Coeff value p value
Alternative-specific constant
 No CRC screening − 2.710 < 0.01*** − 2.620 < 0.01*** 0.517 0.23 − 0.407 0.91
Attributes (main effects)
 Scaled (/10) effectiveness 0.020 < 0.01*** 0.018 < 0.01*** 0.008 0.20 0.016 0.04
 False negative − 0.048 < 0.01*** − 0.052 < 0.01*** 0.001 0.94 − 0.022 0.15
 Frequency
  Every year 0.133 0.127 − 0.132 − 0.176
  Every 2 years 0.144 0.02** 0.214 < 0.01*** 0.335 < 0.01*** 0.342 < 0.01***
  Every 3 years − 0.277 < 0.01*** − 0.341 < 0.01*** − 0.203 0.09* − 0.166 0.18
 Waiting time diagn test
  1 week − 0.033 − 0.180 − 0.116 − 0.096
  2 weeks 0.034 0.58 0.241 < 0.01*** 0.174 0.01*** 0.194 < 0.01***
  3 weeks − 0.001 0.99 − 0.061 < 0.01*** − 0.058 0.40 − 0.099 0.15
 Waiting time f-up test
  2 weeks − 0.091 0.131 0.239 0.218
  4 weeks 0.119 0.06* 0.036 0.40 0.019 0.74 0.048 0.36
  8 weeks − 0.028 0.66 − 0.167 < 0.01*** − 0.258 < 0.01*** − 0.265 < 0.01***
Two-way interactions
 Scaled (/10)
  Eff × fneg 0.001 0.64 0.001 0.55 0.001 0.51 0.002 0.18
 Scaled (/10)
  Eff × freq2 0.008 0.59 − 0.021 0.03** − 0.032 0.01*** − 0.032 0.01***
 Scaled (/10)
  Eff × freq3 − 0.019 0.23 0.026 0.01*** 0.047 < 0.01*** 0.049 < 0.01***
 Scaled (/100)
  Eff × waitdiag2 0.003 0.85 − 0.009 0.35 − 0.009 0.43 − 0.012 0.26
 Scaled (/100)
Eff × waitdiag3 0.004 0.80 0.018 0.08* 0.015 0.22 0.020 0.08*
 Scaled (/10)
  Eff × waitfup4 − 0.185 0.22 − 0.017 0.86 0.062 0.60 0.005 0.97
 Scaled (/10)
  Eff × waitfup8 − 0.281 0.05** 0.085 0.37 0.054 0.64 0.083 0.44
Scale heterogeneity
 Age > 65 year – − 0.356 < 0.01*** 0.633 < 0.01*** 0.743 0.11
 Did not have (had) cancer – 0.285 < 0.01*** − 0.090 < 0.01*** − 0.122 0.31
 Rather deliberative decision-making – 0.403 < 0.01*** 0.493 < 0.01*** 0.352 < 0.01***
 Bad experience – − 2.410 < 0.01*** − 0.333 0.09* − 0.541 0.17
 Health literacy – − 0.246 < 0.01*** 0.104 0.09* 0.059 0.51
 Living alone – 0.337 < 0.01*** 0.562 < 0.01*** 0.540 < 0.01***
 Male – 0.253 < 0.01*** − 0.456 < 0.01*** − 0.213 0.04
 Good nummeracy – 0.279 < 0.01*** − 0.575 < 0.01*** − 0.350 < 0.01***
 Did not have screening experience – − 1.490 < 0.01*** − 0.128 0.07* − 0.132 0.22
Systematic preference heterogeneity
 Age > 65 year × constant ‘no screen-
ing’
– – 1.730 < 0.01*** 1.690 0.40
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Table 4  (continued)
Utility function Model A Model B Model C Model D
Model MNL model HMNL model HMNL model + 
systematic preference 
heterogeneity
HMNL model + 
systematic preference 
heterogeneity + random 
opt-out utility
Coeff value p value Coeff value p value Coeff value p value Coeff value p value
 Age > 65 year × eff – – − 0.021 < 0.01*** − 0.026 < 0.01***
 Age > 65 year × fneg – – 0.033 < 0.01*** 0.040 < 0.01***
 Age > 65 year × freq2 – – − 0.111 0.02** − 0.132 0.01***
 Age > 65 year × freq3 – – 0.149 0.01*** 0.165 0.01***
 Age > 65 year × waitdiagn2 – – − 0.033 0.44 − 0.051 0.22
 Age > 65 year × waitdiagn3 – – − 0.130 0.01*** − 0.100 0.04**
 Attitude for × constant ‘no screening’ – – − 3.760 < 0.01*** − 15.500 < 0.01***
 Attitude for × eff – – 0.020 < 0.01*** 0.014 0.02**
 Attitude for × fneg – – − 0.047 < 0.01*** − 0.035 < 0.01***
 Attitude for × freq2 – – 0.067 0.43 0.065 0.44
 Attitude for × freq3 – – − 0.449 < 0.01*** − 0.503 < 0.01***
 No cancer × constant ‘no screening’ – – − 1.060 < 0.01*** − 4.740 0.07*
 No cancer × fneg – – − 0.011 0.10* − 0.009 0.16
 Crc in family × eff – – − 0.005 0.09* − 0.007 0.06*
 Crc in family × fneg – – 0.021 < 0.01*** 0.020 < 0.01***
 Crc in family × waitdiagn2 – – − 0.081 0.06* − 0.074 0.08*
 Crc in family × waitdiagn3 – – 0.092 0.05** 0.078 0.10*
 Deliberative DM style × constant ‘no 
screening’
– – − 0.408 0.07* − 4.910 0.05**
 Deliberative DM style × fneg – – − 0.013 0.02** − 0.015 0.02**
 Deliberative DM style × freq2 – – − 0.076 0.08* − 0.075 0.07*
 Deliberative DM style × freq3 – – 0.080 0.09* 0.085 0.07*
 High education × constant ‘no screen-
ing’
– – − 0.859 < 0.01*** − 2.990 0.19
 High education × fneg – – − 0.011 0.04** − 0.012 0.02**
 Bad experience × fneg – – − 0.032 < 0.01*** − 0.036 0.30
 Bad experience × freq2 – – 0.366 0.04** 0.539 0.09*
 Bad experience × freq3 – – − 0.255 0.17 − 0.179 0.48
 Last month GP visit × eff – – − 0.008 0.01*** − 0.009 0.01***
 Last month GP visit × fneg – – 0.015 < 0.01*** 0.014 0.02**
 Last month GP visit × freq2 – – 0.007 0.87 0.015 0.71
 Last month GP visit × freq3 – – − 0.136 0.01*** − 0.123 0.01***
 Last month GP visit × waitdiagn2 – – − 0.100 0.01*** − 0.086 0.03**
 Last month GP visit × waitdiagn3 – – 0.064 0.14 0.056 0.18
 Good health × constant ‘no screening’ – – − 0.636 < 0.01*** 0.144 0.95
 Good health × fneg – – − 0.011 0.06* − 0.009 0.11
 Good health × freq2 – – 0.086 0.07* 0.090 0.05**
 Good health × freq3 – – − 0.061 0.24 − 0.060 0.22
 Good health literacy × constant ‘no 
screening’
– – 0.628 < 0.01*** 0.677 0.73
 Good health literacy × fneg – – 0.012 0.02** 0.011 0.05**
 Good health literacy × freq2 – – − 0.103 0.02** − 0.091 0.02**
 Good health literacy × freq3 – – 0.057 0.22 0.066 0.13
 Last month hospital visit × eff – – 0.005 0.08** 0.002 0.44
 Living alone × constant ‘ no screening’ – – 0.924 < 0.01*** 1.110 0.58
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Assuming a base-case respondent and a realistic CRC 
screening scenario, the probability to opt for CRC screening 
was 75.3%, which corresponds to a non-participation rate of 
24.7%. One-way changes in screening characteristics and 
respondents’ characteristics changed this non-participation 
rate from 21.7% up to 28.0% (Fig. 2) and from 8.4% up to 
75.5% (Fig. 3), respectively.
Table 4  (continued)
Utility function Model A Model B Model C Model D
Model MNL model HMNL model HMNL model + 
systematic preference 
heterogeneity
HMNL model + 
systematic preference 
heterogeneity + random 
opt-out utility
Coeff value p value Coeff value p value Coeff value p value Coeff value p value
 Living alone × freq2 – – − 0.064 0.14 − 0.073 0.07*
 Living alone × freq3 – – 0.230 < 0.01*** 0.206 < 0.01***
 Living alone × wait f-up4 – – − 0.037 0.34 − 0.047 0.19
 Living alone × wait f-up8 – – 0.076 0.05** 0.080 0.03**
 Male × constant ‘ no screening’ – – − 1.300 < 0.01*** − 1.360 0.53
 Male × fneg – – − 0.013 0.06* − 0.006 0.33
 Male × freq2 – – 0.100 0.08* 0.073 0.13
 Male × freq3 – – − 0.224 < 0.01*** − 0.151 0.02**
 Male × wait diagn2 – – 0.014 0.78 − 0.010 0.79
 Male × wait diagn3 – – 0.107 0.04** 0.057 0.17
 Good numeracy × constant ‘no screen-
ing’
– – − 1.720 < 0.01*** − 0.030 0.99
 Good numeracy × eff – – 0.028 < 0.01*** 0.024 < 0.01***
 Good numeracy × fneg – – − 0.064 < 0.01*** − 0.052 < 0.01***
 Screening experience × constant ‘ no 
screening’
– – 1.990 < 0.01*** 7.180 0.01***
 No screening experience × freq2 – – − 0.119 0.08* − 0.123 0.06*
 No screening experience × freq3 – – − 0.031 0.66 − 0.056 0.43
 No screening experience × wait f-up4 – – − 0.017 0.76 − 0.001 0.99
 No screening experience × wait f-up8 – – 0.236 < 0.01*** 0.184 < 0.01***
Random opt-out utility (s.d. of ASC) – – – 10.200 < 0.01***
Goodness-of-fit
 LL − 5614 − 5265 − 4778 − 4084
 Number Free Param. 16 25 86 87
 AIC 1.734 1.629 1.497 1.284
 BIC 1.743 1.644 1.551 1.338
Respondents 406 406 406 406
CRC screening uptake
 Observed 92.9 % 92.9 % 92.9 % 92.9 %
 Predicted
  Mean 84.9 % 86.5 % 88.0 % 90.6 %
  Delta − 8.0 % − 6.4 % − 4.9 % − 2.3 %
  Lower bound CI 81.1 % 82.7 % 84.4 % 87.4 %
  Upper bound CI 88.3 % 89.6 % 90.9 % 93.3 %
Proportion of choices that were predicted 
correctly at an individual level
79.9 % 83.0 % 87.9 % 97.1 %
AIC Akaike Information Criterion, ASC alternative specific constant, ascn alternative specific constant opt-out alternative, BIC Bayesian Infor-
mation Criterion, CI confidence interval, coeff coefficient, CRC colorectal cancer, diagn diagnostic, DM decision making, eff effectiveness, fneg 
false negative, freq  frequency, f-up follow-up, GP general practitioner, HMNL heteroscedastic multinomial logit, LL log-likelihood, MNL multi-
nomial logit, s.d. standard deviation, *p < 0.10; **p < 0.05; ***p < 0.01
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From the screening characteristics, the risk of a false-
negative FIT outcome had the strongest impact on the non-
participation rate in CRC screening (Fig. 2). However, a 
respondent’s characteristics had an even stronger impact on 
non-participation. The strongest impact on non-participation 
was the respondent’s general attitude towards CRC screen-
ing followed by whether the respondent had participated in 
a cancer screening programme before, the decision style of 
the respondent and the educational level of the respondent 
(Fig. 3).
4  Discussion
There are just a handful of DCE studies investigating pref-
erences for CRC screening (although none of them focused 
on how screening and individuals’ characteristics impact on 
CRC screening non-participation) [11, 14–20]. Several of 
these DCE studies found that risk reduction of CRC-related 
mortality is an important screening characteristic for the 
individual to prefer CRC screening over no screening [11, 
14, 17], which is in line with our findings. Our finding that 
the screening interval has an influence on preferences for 
CRC screening was also found by Hol et al. [11], and van 
Dam et al. [17]. Benning et al. [14] investigated whether sev-
eral sociodemographic variables impacted participants’ pref-
erences for CRC screening. They found that being younger, 
higher educated, experienced with cancer screening and 
female positively impacted CRC screening participation. 
Apart from sex, these results are in-line with our findings. 
Interestingly, in our DCE study with the heteroscedastic 
multinomial logit model specification, we found that having 
a more deliberative decision style resulted in higher choice 
consistency. This result was also found in a DCE study of de 
Bekker-Grob et al. [21] concerning external validity of DCE 
outcomes, which raises the question whether the decision 
style should be measured and taken into account into future 
health-related DCE studies.
Our study showed that if the individual had a negative 
attitude towards CRC screening and/or if the individual had 
not opted for a cancer screening programme before, this 
individual would be less likely to participate in CRC screen-
ing. Hence, to reduce CRC screening non-participation 
substantially, tackling the negative attitude of individuals 
Fig. 2  One-way impact of screening characteristics on non-participa-
tion in colorectal cancer (CRC) screening. Note: The base case is a 
‘low educated male individual aged 55–64 years with a positive atti-
tude for CRC screening, who has not had cancer. He has good health 
literacy and numeracy skills and a non-deliberative decision style, has 
screening experience, but has not experienced a bad screening test 
result yet. He does not have CRC diagnosed in his family, has a good 
health condition, did not visit the general practitioner (GP) or hospi-
tal in the last month, and is living together with a partner or family 
member. He is invited to join a CRC screening programme that has 
an effectiveness of 40%, has a 25% risk of a false-negative outcome, 
a screening frequency of every 2 years, a 2-week waiting time for fae-
cal immunochemical testing results and a 4-week waiting time for a 
colonoscopy follow-up (f-up) test.’ diagn diagnostic
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towards population-based screening is important. Focusing 
on health promotion campaigns, tailored communication 
and/or awareness is a first next step. For example, by clari-
fying that an individual aged 55–75 years can reduce his/her 
risk of CRC-related mortality by joining the CRC screening 
programme, and that they do not have to pay for this screen-
ing test. Further research is warranted to investigate whether 
sending a more tailored letter to non-participants will reduce 
the negative attitude and as such the non-participation rate 
substantially.
Despite the fact that the present study used a mixed-meth-
ods approach that led to results with a high degree of valid-
ity, our study had several limitations. A potential weakness 
of the present study is that several attributes included in the 
DCE contained numbers and rates. This might have caused 
difficulties with completing the choice tasks; although 90.6% 
of the respondents reported that they did not find the DCE 
questions difficult. Second, the percentage of respondents 
(92.9%) who stated they would participate in CRC screening 
was substantially higher than current Dutch CRC screening 
practice (72.7%); therefore, we cannot exclude that selection 
bias may exist in our sample (noteworthy: another explana-
tion might be that the intention to participate is not equal to 
participation in CRC screening). Finally, the current results 
could gain credibility if future research compares, for exam-
ple using the approach of de Bekker-Grob et al. [21], the 
predicted CRC screening non-participation of respondents 
with their actual behaviour in CRC screening.
5  Conclusions
This study showed that although screening characteristics 
proved to influence non-participation in CRC screening, a 
respondent’s characteristics had a much higher impact on 
CRC screening non-participation; particularly, the indi-
vidual’s general attitude towards CRC screening followed 
by whether the respondent had participated in a cancer 
Fig. 3  One-way impact of respondent characteristics on non-partici-
pation in colorectal cancer (CRC) screening. Note: The base case is a 
‘low educated male individual aged 55–64 years with a positive atti-
tude for CRC screening, who has not had cancer. He has good health 
literacy and numeracy skills and a non-deliberative decision style, has 
screening experience, but did not experience a bad (i.e. unfavoured) 
screening test result yet. He does not have CRC diagnosed in his 
family, has a good health condition, did not visit the general practi-
tioner (GP) or hospital in the last month, and is living together with a 
partner or family member. He is invited to join a CRC screening pro-
gramme that has an effectiveness of 40%, has a 25% risk of a false-
negative outcome, a screening frequency of every 2 years, a 2-week 
waiting time for faecal immunochemical testing results and a 4-week 
waiting time for a colonoscopy follow-up test’
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screening programme before, the decision style and the edu-
cational level of the respondent. Policy makers and physi-
cians can use these insights to improve and tailor their com-
munication plans regarding CRC screening for unscreened 
individuals.
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